Rosemary A. Henik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rosemary A. Henik has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Lisa J. Wenholz
Department of Medical Sciences, University of Wisconsin-Madison School of Veterinary Medicine, 2015 Linden Drive, Madison, WI 53706, United States
2 shared publicationsMichele K. Dolson
Veterinary Medical Teaching Hospital, University of Wisconsin-Madison School of Veterinary Medicine, 2015 Linden Drive, Madison, WI 53706, United States
2 shared publicationsHeidi A. Fay
1 shared publicationJenna E. Buley
1 shared publicationJennifer L Steele
University of Wisconsin-Madison, Department ofMedical Sciences, Madison, WI 53706, USA
1 shared publicationRebecca L. Stepien
Department of Medical Sciences, University of Wisconsin-Madison School of Veterinary Medicine, 2015 Linden Drive, Madison, WI 53706, United States
1 shared publication
Latest Publications
- 1 December 2009
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 235 (11) , 1275-1276
What Is Your Diagnosis?
- 1 December 2009
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 235 (11) , 1275-1276
What Is Your Diagnosis?
- 1 December 2008
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 10 (6) , 577-582
Efficacy of atenolol as a single antihypertensive agent in hyperthyroid cats
β-Adrenergic blockers, particularly atenolol, are often recommended for the tachycardia and hypertension that accompany hyperthyroidism; however, the effects of monotherapy with atenolol on both systolic blood pressure (SBP) and heart rate (HR) have not been reported. Twenty hyperthyroid cats with SBP ≥160 mmHg were studied retrospectively to investigate the SBP and HR lowering effects of atenolol. Median pre-treatment SBP and HR for all cats were 186.5 mmHg and 231 beats/min, respectively. All cats were treated with atenolol at a dosage of 1–2 mg/kg PO q 12 h for a minimum of 5 days prior to reassessment and treatment with radioactive iodine. SBP and HR both decreased following atenolol therapy in this group of cats to median values of 171.5 mmHg ( P=0.0088) and 185/min ( P=0.0003). However, when successful clinical control of hypertension was defined as a post-treatment SBP <160 mmHg, atenolol monotherapy was ineffective in 70% of the cases. There was no statistically significant difference in baseline serum total thyroxine or atenolol dosage between clinical responders and non-responders. While atenolol effectively reduces HR in most cats with hyperthyroidism, elevated SBP is poorly controlled, and the addition of another vasodilator such as amlodipine or an angiotensin converting enzyme inhibitor is needed to treat associated hypertension.
- 1 December 2008
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 10 (6) , 577-582
Efficacy of atenolol as a single antihypertensive agent in hyperthyroid cats
β-Adrenergic blockers, particularly atenolol, are often recommended for the tachycardia and hypertension that accompany hyperthyroidism; however, the effects of monotherapy with atenolol on both systolic blood pressure (SBP) and heart rate (HR) have not been reported. Twenty hyperthyroid cats with SBP ≥160 mmHg were studied retrospectively to investigate the SBP and HR lowering effects of atenolol. Median pre-treatment SBP and HR for all cats were 186.5 mmHg and 231 beats/min, respectively. All cats were treated with atenolol at a dosage of 1–2 mg/kg PO q 12 h for a minimum of 5 days prior to reassessment and treatment with radioactive iodine. SBP and HR both decreased following atenolol therapy in this group of cats to median values of 171.5 mmHg ( P=0.0088) and 185/min ( P=0.0003). However, when successful clinical control of hypertension was defined as a post-treatment SBP <160 mmHg, atenolol monotherapy was ineffective in 70% of the cases. There was no statistically significant difference in baseline serum total thyroxine or atenolol dosage between clinical responders and non-responders. While atenolol effectively reduces HR in most cats with hyperthyroidism, elevated SBP is poorly controlled, and the addition of another vasodilator such as amlodipine or an angiotensin converting enzyme inhibitor is needed to treat associated hypertension.
- 1 August 2005
- Published by Elsevier in Clinical Techniques in Small Animal Practice
- Vol. 20 (3) , 144-150
How to Obtain a Blood Pressure Measurement
- 1 August 2005
- Published by Elsevier in Clinical Techniques in Small Animal Practice
- Vol. 20 (3) , 144-150
How to Obtain a Blood Pressure Measurement
- 1 January 2002
- Vol. 3 (2) , 157-66
Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease.
Hypertension is commonly associated with chronic renal disease in cats, and inappropriate activation of the renin-angiotensin-aldosterone system (RAAS) may contribute to the hypertensive state. Angiotensin-converting enzyme (ACE) inhibitors are commonly administered when hypertension is present to decrease plasma concentrations of angiotensin II and aldosterone, which cause vasoconstriction and sodium and water retention, respectively. The study reported here was conducted over a 6-month period to assess the effects of two commonly prescribed ACE inhibitors, enalapril and benazepril, on the activity of the RAAS and blood pressure in 16 spontaneously hypertensive cats with chronic renal disease. Plasma aldosterone and plasma renin activity were not significantly affected by ACE inhibitors in hypertensive cats, and systolic blood pressure did not decrease below 170 mm Hg with ACE inhibitor monotherapy in 14 of 16 cats. These results suggest that continued activation of the RAAS is present in hypertensive cats despite treatment with an ACE inhibitor, and ACE inhibitors should not be used as first-line antihypertensive treatment in hypertensive cats.
- 1 January 2002
- Vol. 3 (2) , 157-66
Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease.
Hypertension is commonly associated with chronic renal disease in cats, and inappropriate activation of the renin-angiotensin-aldosterone system (RAAS) may contribute to the hypertensive state. Angiotensin-converting enzyme (ACE) inhibitors are commonly administered when hypertension is present to decrease plasma concentrations of angiotensin II and aldosterone, which cause vasoconstriction and sodium and water retention, respectively. The study reported here was conducted over a 6-month period to assess the effects of two commonly prescribed ACE inhibitors, enalapril and benazepril, on the activity of the RAAS and blood pressure in 16 spontaneously hypertensive cats with chronic renal disease. Plasma aldosterone and plasma renin activity were not significantly affected by ACE inhibitors in hypertensive cats, and systolic blood pressure did not decrease below 170 mm Hg with ACE inhibitor monotherapy in 14 of 16 cats. These results suggest that continued activation of the RAAS is present in hypertensive cats despite treatment with an ACE inhibitor, and ACE inhibitors should not be used as first-line antihypertensive treatment in hypertensive cats.